1. Home
  2. REVB vs ULY Comparison

REVB vs ULY Comparison

Compare REVB & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.63

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.26

Market Cap

5.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
REVB
ULY
Founded
2020
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REVB
ULY
Price
$0.63
$2.26
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.50
AVG Volume (30 Days)
5.3M
1.5M
Earning Date
03-05-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$127,932,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$1.74
52 Week High
$17.04
$17.99

Technical Indicators

Market Signals
Indicator
REVB
ULY
Relative Strength Index (RSI) 30.42 46.53
Support Level $0.71 $2.12
Resistance Level $0.96 $2.75
Average True Range (ATR) 0.14 0.35
MACD -0.01 -0.07
Stochastic Oscillator 4.73 15.13

Price Performance

Historical Comparison
REVB
ULY

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: